• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病缓解或进展对日本心血管疾病发病率的影响:使用全国索赔数据库的历史性队列研究。

Impact of diabetes remission or progression on the incidence of cardiovascular disease in Japan: historical cohort study using a nationwide claims database.

作者信息

Shimayama Chihiro, Fujihara Kazuya, Khin Laymon, Takizawa Hiroki, Horikawa Chika, Sato Takaaki, Kitazawa Masaru, Matsubayashi Yasuhiro, Yamada Takaho, Sone Hirohito

机构信息

Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, 1-757 Asahimachi-dori, Chuo Ward, Niigata, 951-8510, Japan.

Kowa Company, Ltd., Tokyo, Japan.

出版信息

Cardiovasc Diabetol. 2025 Jan 22;24(1):37. doi: 10.1186/s12933-025-02578-y.

DOI:10.1186/s12933-025-02578-y
PMID:39844263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11756120/
Abstract

BACKGROUND

Previous studies demonstrated that diabetes remission can occur during intensive intervention and in real-world settings. However, the impact of diabetes remission in real-world settings on the incidence of cardiovascular disease (CVD) remains unclear.

METHODS

This retrospective cohort study included 299,967 individuals aged 20-72 years who underwent multiple checkups between 2008 and 2020 and completed ≥ 3 years of follow-up. Patients were divided into four groups according to changes in glycated hemoglobin levels and the use of diabetes medications during the 1-year baseline period: diabetes mellitus (DM)+/no remission, DM+/remission, DM-/no progression, and DM-/progression. The risk of CVD was evaluated using multivariable Cox regression analysis.

RESULTS

The median follow-up period was 5.0 years. The rates of CVD in the DM+/no remission, DM+/remission, DM-/no progression, and DM-/progression groups were 7.96, 4.76, 1.99, and 5.47 per 1000 person-years, respectively. Compared with DM+/no remission, DM+/remission reduced the risk of CVD [hazard ratio (HR) = 0.71, 95% confidence interval (CI) = 0.57-0.89]. Meanwhile, the HR for CVD in the DM+/remission group was 0.75 (95% CI = 0.56-0.99) for change in BMI ≤ 0%, versus 0.66 (95% CI = 0.45-0.96) for change in BMI > 0%.

CONCLUSIONS

In a real-world setting without intensive intervention, diabetes remission decreased the risk of CVD by approximately 30% regardless of changes in BMI, suggesting that diabetes remission can prevent CVD without weight loss in routine care and emphasizing the importance of achieving remission.

摘要

背景

先前的研究表明,强化干预期间及现实环境中均可出现糖尿病缓解。然而,现实环境中糖尿病缓解对心血管疾病(CVD)发病率的影响仍不明确。

方法

这项回顾性队列研究纳入了299967名年龄在20至72岁之间的个体,这些个体在2008年至2020年间接受了多次检查,并完成了≥3年的随访。根据糖化血红蛋白水平的变化以及1年基线期内糖尿病药物的使用情况,将患者分为四组:糖尿病(DM)+/未缓解、DM+/缓解、DM-/无进展和DM-/进展。使用多变量Cox回归分析评估CVD风险。

结果

中位随访期为5.0年。DM+/未缓解、DM+/缓解、DM-/无进展和DM-/进展组的CVD发生率分别为每1000人年7.96、4.76、1.99和5.47。与DM+/未缓解相比,DM+/缓解降低了CVD风险[风险比(HR)=0.71,95%置信区间(CI)=0.57-0.89]。同时,DM+/缓解组中,体重指数(BMI)变化≤0%时CVD的HR为0.75(95%CI=0.56-0.99),而BMI变化>0%时为0.66(95%CI=0.45-0.96)。

结论

在没有强化干预的现实环境中,无论BMI如何变化,糖尿病缓解均可使CVD风险降低约30%,这表明在常规护理中,糖尿病缓解无需减重即可预防CVD,并强调了实现缓解的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c19/11756120/2c0fbc20c5c5/12933_2025_2578_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c19/11756120/92b5960be7f9/12933_2025_2578_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c19/11756120/2c0fbc20c5c5/12933_2025_2578_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c19/11756120/92b5960be7f9/12933_2025_2578_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c19/11756120/2c0fbc20c5c5/12933_2025_2578_Fig2_HTML.jpg

相似文献

1
Impact of diabetes remission or progression on the incidence of cardiovascular disease in Japan: historical cohort study using a nationwide claims database.糖尿病缓解或进展对日本心血管疾病发病率的影响:使用全国索赔数据库的历史性队列研究。
Cardiovasc Diabetol. 2025 Jan 22;24(1):37. doi: 10.1186/s12933-025-02578-y.
2
Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese.日本人群中既往脑血管疾病和血糖状况对新发脑血管疾病的影响
Cardiovasc Diabetol. 2021 Sep 3;20(1):174. doi: 10.1186/s12933-021-01367-7.
3
Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study.经皮冠状动脉介入治疗后严格血糖控制(术前 HbA1c<6.5%)增加日本接受药物治疗的糖尿病患者心血管死亡率:一项 10 年随访研究。
Cardiovasc Diabetol. 2020 Feb 18;19(1):21. doi: 10.1186/s12933-020-00996-8.
4
Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study.在阿联酋高危男性和女性中心血管疾病及其相关危险因素的发生率:一项 9 年回顾性队列研究。
BMC Cardiovasc Disord. 2019 Jun 17;19(1):148. doi: 10.1186/s12872-019-1131-2.
5
Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.中国基层医疗 2 型糖尿病患者多因素治疗靶点及血红蛋白 A1c、血压和低密度脂蛋白胆固醇的相对重要性对心血管疾病的影响:基于人群的回顾性队列研究。
J Am Heart Assoc. 2017 Aug 17;6(8):e006400. doi: 10.1161/JAHA.117.006400.
6
Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.2型糖尿病和代谢相关脂肪性肝病/相关严重肝病状态的变化与发生心血管疾病风险的关联。
Diabetes Obes Metab. 2025 Apr;27(4):2035-2043. doi: 10.1111/dom.16196. Epub 2025 Jan 15.
7
Differences in the association of lifestyle-related modifiable risk factors with incident cardiovascular disease between individuals with and without diabetes.患有糖尿病和未患糖尿病的个体在与心血管疾病发生相关的生活方式可改变风险因素方面的差异。
Eur J Prev Cardiol. 2025 Apr 2;32(5):376-383. doi: 10.1093/eurjpc/zwae221.
8
Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience.糖尿病对接受左心室辅助装置支持的患者预后的影响:一项单机构9年经验。
Circ Heart Fail. 2017 Nov;10(11). doi: 10.1161/CIRCHEARTFAILURE.117.004213.
9
Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus.胰岛素治疗对合并糖尿病的急性心力衰竭患者死亡率的影响。
Cardiovasc Diabetol. 2021 Sep 8;20(1):180. doi: 10.1186/s12933-021-01370-y.
10
Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study.糖尿病对急性心力衰竭患者死亡率的影响:一项前瞻性队列研究。
Cardiovasc Diabetol. 2020 May 2;19(1):49. doi: 10.1186/s12933-020-01026-3.

本文引用的文献

1
Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study.2型糖尿病缓解对长期健康结局的影响:来自“展望”(Look AHEAD)研究的结果
Diabetologia. 2024 Mar;67(3):459-469. doi: 10.1007/s00125-023-06048-6. Epub 2024 Jan 18.
2
Remission of type 2 diabetes: always more questions, but enough answers for action.2 型糖尿病缓解:问题层出不穷,但已有足够答案付诸行动。
Diabetologia. 2024 Apr;67(4):602-610. doi: 10.1007/s00125-023-06069-1. Epub 2024 Jan 8.
3
Type 2 Diabetes Remission: A New Mission in Diabetes Care.
2型糖尿病缓解:糖尿病护理的新使命。
Diabetes Care. 2024 Jan 1;47(1):47-49. doi: 10.2337/dci23-0062.
4
Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus.澳大利亚初级保健中强化生活方式干预对早期 2 型糖尿病缓解的效果:DiRECT-Aus 研究。
Diabetes Care. 2024 Jan 1;47(1):66-70. doi: 10.2337/dc23-0781.
5
Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes.香港早发性与晚发性 2 型糖尿病患者胰岛β细胞功能的比较。
Diabetes Res Clin Pract. 2023 Nov;205:110954. doi: 10.1016/j.diabres.2023.110954. Epub 2023 Oct 14.
6
Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: Analysis of nationwide patient registry in Japan (JDDM74).真实世界环境中体重指数降幅与 2 型糖尿病患者缓解的关系:日本全国患者注册登记研究(JDDM74)分析。
Diabetes Obes Metab. 2023 Nov;25(11):3125-3135. doi: 10.1111/dom.15206. Epub 2023 Jul 7.
7
Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry (JDDM73).日本 2 型糖尿病缓解和复发的发生率和预测因素:一项全国性患者注册研究(JDDM73)分析。
Diabetes Obes Metab. 2023 Aug;25(8):2227-2235. doi: 10.1111/dom.15100. Epub 2023 May 8.
8
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes.糖化血红蛋白(A1C)、空腹血糖及口服葡萄糖耐量试验标准在定义糖尿病缓解方面的一致性
Diabetes Care. 2023 Mar 1;46(3):e83-e84. doi: 10.2337/dc22-2406.
9
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.在2型糖尿病患者中,使用每周一次的葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1受体激动剂替尔泊肽实现血糖目标且无低血糖发生,同时伴有体重减轻:SURPASS-1至-5研究的事后分析
Diabetes Obes Metab. 2023 Apr;25(4):965-974. doi: 10.1111/dom.14943. Epub 2022 Dec 27.
10
Role of insulin action in the pathogenesis of diabetic complications.胰岛素作用在糖尿病并发症发病机制中的作用。
Diabetol Int. 2022 Sep 7;13(4):591-598. doi: 10.1007/s13340-022-00601-1. eCollection 2022 Oct.